SCHEMBL419651

SCHEMBL419651

COC(=O)c1cc(Cl)ccc1NC(=O)c1ccc(-c2ccccc2)o1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.74
ALDH1A1 P00352 4/20 0.74
NPC1 O15118 2/20 0.74
SMN1; SMN2 Q16637 2/20 0.74
KDM4E B2RXH2 3/20 0.61
RAB9A P51151 2/20 0.61
HSD17B10 Q99714 2/20 0.56
KMT2A Q03164 1/20 0.56
S1PR4 O95977 6/20 0.55
MAPT P10636 2/20 0.55
GAA P10253 1/20 0.55
HTR1A P08908 1/20 0.52
ADORA3 P0DMS8 1/20 0.52
CNR1 P21554 1/20 0.52
DRD1 P21728 1/20 0.52
HTR2A P28223 1/20 0.52
ADORA2A P29274 1/20 0.52
OPRM1 P35372 1/20 0.52
SCN5A Q14524 1/20 0.52
SCN9A Q15858 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL418049 0.89 SERPINE1 (0.63) HPGDALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL420688 0.81 SLC6A4 (0.62) HPGDALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL420185 0.79 SERPINE1 (0.77) HPGDALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL420932 0.78 MEN1 (0.57) HPGDALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL417055 0.76 SERPINE1 (0.80) HPGDALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL7040693 0.75 PPARG (0.60) ALDH1A1KDM4EKMT2AMAPTNPSR1
SCHEMBL3784326 0.75 KDM4E (0.62) HPGDALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL6818580 0.74 ALDH1A1 (0.56) HPGDALDH1A1SMN1; SMN2KDM4ERAB9A
SCHEMBL896770 0.74 ALDH1A1 (0.69) HPGDALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL7038586 0.74 PPARG (0.61) HPGDALDH1A1NPC1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 HPGD 904/4885ALDH1A1 1450/4885NPC1 893/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 HPGD 904/4885ALDH1A1 1450/4885NPC1 893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.